Journal
CANCER
Volume 121, Issue 10, Pages 1712-1719Publisher
WILEY
DOI: 10.1002/cncr.29237
Keywords
low-grade glioma; proton therapy; proton radiation; late effects; neurocognitive function; pituitary function; neuroendocrine function; quality of life
Categories
Funding
- Pappas Award in Brain Tumor Research
- Massachusetts General Hospital
- Federal Share of program by Massachusetts General Hospital on Proton Therapy Research and Treatment Center [C06 CA059267]
Ask authors/readers for more resources
BACKGROUNDIn this prospective study, the authors evaluated potential treatment toxicity and progression-free survival in patients with low-grade glioma who received treatment with proton radiation therapy. METHODSTwenty patients with World Health Organization grade 2 glioma who were eligible for radiation therapy were enrolled in a prospective, single-arm trial of proton therapy. The patients received proton therapy at a dose of 54 Gy (relative biological effectiveness) in 30 fractions. Comprehensive baseline and regular post-treatment evaluations of neurocognitive function, neuroendocrine function, and quality of life (QOL) were performed. RESULTSAll 20 patients (median age, 37.5 years) tolerated treatment without difficulty. The median follow-up after proton therapy was 5.1 years. At baseline, intellectual functioning was within the normal range for the group and remained stable over time. Visuospatial ability, attention/working memory, and executive functioning also were within normal limits; however, baseline neurocognitive impairments were observed in language, memory, and processing speed in 8 patients. There was no overall decline in cognitive functioning over time. New endocrine dysfunction was detected in 6 patients, and all but 1 had received direct irradiation of the hypothalamic-pituitary axis. QOL assessment revealed no changes over time. The progression-free survival rate at 3 years was 85%, but it dropped to 40% at 5 years. CONCLUSIONSPatients with low-grade glioma tolerate proton therapy well, and a subset develops neuroendocrine deficiencies. There is no evidence for overall decline in cognitive function or QOL. Cancer 2015;121:1712-1719. (c) 2015 American Cancer Society. Patients with low-grade glioma can safely and effectively receive proton radiation therapy with no added neurocognitive impairment or quality-of-life decrement based on early experience. Radiation dose to the pituitary correlates with early neuroendocrine dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available